Canine Cognitive Dysfunction (CCD), Alzheimer’s Disease (AD), and β-Amyloid Accumulation: Using CCD as a Reference for the Development of AD Treatments and Therapies
Date
4-10-2021
Location
Online
Description
I researched the similarities and differences between Canine Cognitive Dysfunction (CCD)—a disease with symptoms and progression pattern that parallels Alzheimer’s Disease (AD)—and AD. I studied how β-amyloid accumulates in various brain regions—such as the prefrontal, occipital, entorhinal and parietal cortices—in canines to determine how β-amyloid accumulation is associated with the development of behaviors signifying cognitive decline observed in CCD and AD—such as changes in the sleep-wake cycle, social interaction, housetraining, and general orientation—in order to understand how neuroscientists may be able to derive new understandings from a canine model with CCD, and apply these developments to humans with AD in order to develop therapies and treatments for AD. I discovered that domestic canines and humans share the same environmental stressors, develop oxidative stress in a similar manner, and β-amyloid accumulation in the canine brain parallels β-amyloid accumulation in the human brain. Additionally, canine response to pharmaceuticals mimics human response to pharmaceuticals.
Presentation Type
Poster
Canine Cognitive Dysfunction (CCD), Alzheimer’s Disease (AD), and β-Amyloid Accumulation: Using CCD as a Reference for the Development of AD Treatments and Therapies
Online
I researched the similarities and differences between Canine Cognitive Dysfunction (CCD)—a disease with symptoms and progression pattern that parallels Alzheimer’s Disease (AD)—and AD. I studied how β-amyloid accumulates in various brain regions—such as the prefrontal, occipital, entorhinal and parietal cortices—in canines to determine how β-amyloid accumulation is associated with the development of behaviors signifying cognitive decline observed in CCD and AD—such as changes in the sleep-wake cycle, social interaction, housetraining, and general orientation—in order to understand how neuroscientists may be able to derive new understandings from a canine model with CCD, and apply these developments to humans with AD in order to develop therapies and treatments for AD. I discovered that domestic canines and humans share the same environmental stressors, develop oxidative stress in a similar manner, and β-amyloid accumulation in the canine brain parallels β-amyloid accumulation in the human brain. Additionally, canine response to pharmaceuticals mimics human response to pharmaceuticals.